Synopsis
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - POWDER;INTRAVENOUS - EQ 250MG BASE/V...DOSAGE - POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50587
DOSAGE - POWDER;INTRAVENOUS - EQ 500MG BASE/V...DOSAGE - POWDER;INTRAVENOUS - EQ 500MG BASE/VIAL;500MG/VIAL
USFDA APPLICATION NUMBER - 50587
Related Excipient Companies
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Cilastatin Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cilastatin Sodium, including repackagers and relabelers. The FDA regulates Cilastatin Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cilastatin Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cilastatin Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cilastatin Sodium supplier is an individual or a company that provides Cilastatin Sodium active pharmaceutical ingredient (API) or Cilastatin Sodium finished formulations upon request. The Cilastatin Sodium suppliers may include Cilastatin Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Cilastatin Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cilastatin Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Cilastatin Sodium active pharmaceutical ingredient (API) in detail. Different forms of Cilastatin Sodium DMFs exist exist since differing nations have different regulations, such as Cilastatin Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cilastatin Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Cilastatin Sodium USDMF includes data on Cilastatin Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cilastatin Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cilastatin Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cilastatin Sodium Drug Master File in Japan (Cilastatin Sodium JDMF) empowers Cilastatin Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cilastatin Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Cilastatin Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cilastatin Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cilastatin Sodium Drug Master File in Korea (Cilastatin Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cilastatin Sodium. The MFDS reviews the Cilastatin Sodium KDMF as part of the drug registration process and uses the information provided in the Cilastatin Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cilastatin Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cilastatin Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cilastatin Sodium suppliers with KDMF on PharmaCompass.
A Cilastatin Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Cilastatin Sodium Certificate of Suitability (COS). The purpose of a Cilastatin Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cilastatin Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cilastatin Sodium to their clients by showing that a Cilastatin Sodium CEP has been issued for it. The manufacturer submits a Cilastatin Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cilastatin Sodium CEP holder for the record. Additionally, the data presented in the Cilastatin Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cilastatin Sodium DMF.
A Cilastatin Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cilastatin Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cilastatin Sodium suppliers with CEP (COS) on PharmaCompass.
A Cilastatin Sodium written confirmation (Cilastatin Sodium WC) is an official document issued by a regulatory agency to a Cilastatin Sodium manufacturer, verifying that the manufacturing facility of a Cilastatin Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cilastatin Sodium APIs or Cilastatin Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Cilastatin Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Cilastatin Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cilastatin Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cilastatin Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cilastatin Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cilastatin Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cilastatin Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cilastatin Sodium suppliers with NDC on PharmaCompass.
Cilastatin Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cilastatin Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cilastatin Sodium GMP manufacturer or Cilastatin Sodium GMP API supplier for your needs.
A Cilastatin Sodium CoA (Certificate of Analysis) is a formal document that attests to Cilastatin Sodium's compliance with Cilastatin Sodium specifications and serves as a tool for batch-level quality control.
Cilastatin Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Cilastatin Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cilastatin Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Cilastatin Sodium EP), Cilastatin Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cilastatin Sodium USP).
LOOKING FOR A SUPPLIER?
